Alzheimers & Dementia

Article	Citations
2021 Alzheimer's disease facts and figures	1563
2022 Alzheimer's disease facts and figures	1146
2023 Alzheimer's disease facts and figures	625
Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020–2060)	387
Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019	319
World‐Wide FINGERS Network: A global approach to risk reduction and prevention of dementia	258
The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease	179
In vivo measurement of widespread synaptic loss in Alzheimer's disease with SV2A PET	174
Hypothesis: Tau pathology is an initiating factor in sporadic Alzheimer's disease	170
The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease	170
Global estimates on the number of persons across the Alzheimer's disease continuum	167
COVID‐19 and dementia: Analyses of risk, disparity, and outcomes from electronic health records in the US	163
Plasma p‐tau181, p‐tau217, and other blood‐based Alzheimer's disease biomarkers in a multi‐ethnic, community study	161
The chronic neuropsychiatric sequelae of COVID‐19: The need for a prospective study of viral impact on brain functioning	138
Changes in cognitive functioning after COVID‐19: A systematic review and meta‐analysis	137
Blood neuro‐exosomal synaptic proteins predict Alzheimer's disease at the asymptomatic stage	135
Tackling challenges in care of Alzheimer's disease and other dementias amid the COVID‐19 pandemic, now and in the future	120
Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum	116
Visualization of neurofibrillary tangle maturity in Alzheimer's disease: A clinicopathologic perspective for biomarker research	115
Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia	112
Vascular contributions to cognitive impairment and dementia (VCID): A report from the 2018 National Heart, Lung, and Blood Institute and National Institute of Neurological Disorders and Stroke Worksho	110
Alzheimer's‐like signaling in brains of COVID‐19 patients	109
GABAergic dysfunction in excitatory and inhibitory (E/I) imbalance drives the pathogenesis of Alzheimer's disease	108
Cognitive impairment in sporadic cerebral small vessel disease: A systematic review and meta‐analysis	98
Prevalence of cerebral amyloid angiopathy: A systematic review and meta‐analysis	97

Acute systemic inflammation exacerbates neuroinflammation in Alzheimer's disease: IL‐1β drives amplified responses in primed astrocytes and neuronal network dysfunction	96
Comparison of serum neurodegenerative biomarkers among hospitalized COVID‐19 patients versus non‐COVID subjects with normal cognition, mild cognitive impairment, or Alzheimer's dementia	92
Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities	92
The Brain Chart of Aging: Machine‐learning analytics reveals links between brain aging, white matter disease, amyloid burden, and cognition in the iSTAGING consortium of 10,216 harmonized MR scans	91
A ketogenic drink improves cognition in mild cognitive impairment: Results of a 6‐month RCT	90
Retinal imaging in Alzheimer's and neurodegenerative diseases	89
World Alzheimer Report 2019: Attitudes to dementia, a global survey	88
Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease	86
Characterization of pre‐analytical sample handling effects on a panel of Alzheimer's disease–related blood‐based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) wor	86
A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR Study	84
The role of mitochondrial dysfunction in Alzheimer's disease pathogenesis	84
Midlife vascular risk factors and risk of incident dementia: Longitudinal cohort and Mendelian randomization analyses in the UK Biobank	82
Gait variability across neurodegenerative and cognitive disorders: Results from the Canadian Consortium of Neurodegeneration in Aging (CCNA) and the Gait and Brain Study	81
Head‐to‐head comparison of clinical performance of CSF phospho‐tau T181 and T217 biomarkers for Alzheimer's disease diagnosis	79
Regional brain iron associated with deterioration in Alzheimer's disease: A large cohort study and theoretical significance	75
The impact of diabetes on cognitive impairment and its progression to dementia	75
Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p‐tau	74
An examination of a novel multipanel of CSF biomarkers in the Alzheimer's disease clinical and pathological continuum	74
The estimation of the global prevalence of dementia from 1990‐2019 and forecasted prevalence through 2050: An analysis for the Global Burden of Disease (GBD) study 2019	73
Diagnostic criteria for apathy in neurocognitive disorders	71
36‐month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer's disease	70
Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: Recommendations of an expert panel	68
Multimorbidity burden and dementia risk in older adults: The role of inflammation and genetics	67
White matter hyperintensity topography in Alzheimer's disease and links to cognition	66
Dementia is an age‐independent risk factor for severity and death in COVID‐19 inpatients	65
Large‐scale plasma proteomic profiling identifies a high‐performance biomarker panel for Alzheimer's disease screening and staging	64
Dementia in Latin America: Paving the way toward a regional action plan	64
Synaptic density and cognitive performance in Alzheimer's disease: A PET imaging study with [11C]UCB‐J	62
Integrative metabolomics‐genomics approach reveals key metabolic pathways and regulators of Alzheimer's disease	60
Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease	58
ENGAGE and EMERGE: Truth and consequences?	58
Repetitive negative thinking is associated with amyloid, tau, and cognitive decline	58
Black and White individuals differ in dementia prevalence, risk factors, and symptomatic presentation	58
Toward a theory‐based specification of non‐pharmacological treatments in aging and dementia: Focused reviews and methodological recommendations	57
Associations of loneliness with risk of Alzheimer's disease dementia in the Framingham Heart Study	57
Plasma Aβ42/40 ratio, p‐tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross‐sectional and longitudinal study in the AIBL cohort	55
Age‐related calcium dysregulation linked with tau pathology and impaired cognition in non‐human primates	54
Education differentially contributes to cognitive reserve across racial/ethnic groups	54
Further understanding the connection between Alzheimer's disease and Down syndrome	54
The worldwide costs of dementia in 2019	53
Role of chronic neuroinflammation in neuroplasticity and cognitive function: A hypothesis	52
Relationships between memory decline and the use of metformin or DPP4 inhibitors in people with type 2 diabetes with normal cognition or Alzheimer's disease, and the role APOE carrier status	51
The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau	51
Sleep characteristics and cerebrospinal fluid biomarkers of Alzheimer's disease pathology in cognitively intact older adults: The CABLE study	51
Extracellular vesicle biomarkers of Alzheimer's disease associated with sub‐clinical cognitive decline in late middle age	51
An accurate fully automated panel of plasma biomarkers for Alzheimer's disease	50
Whole‐genome sequencing reveals new Alzheimer's disease–associated rare variants in loci related to synaptic function and neuronal development	49
Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance	49
Plasma and CSF biomarkers in a memory clinic: Head‐to‐head comparison of phosphorylated tau immunoassays	49
Emerge and Engage topline results: Phase 3 studies of aducanumab in early Alzheimer’s disease	48

Traditional Chinese medicine for dementia	48
Diversity of transcriptomic microglial phenotypes in aging and Alzheimer's disease	47
Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease	46
Stroke and dementia, leading causes of neurological disability and death, potential for prevention	45
Plasma hydrogen sulfide: A biomarker of Alzheimer's disease and related dementias	44
Current directions in tau research: Highlights from Tau 2020	43
Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification	43
MarkVCID cerebral small vessel consortium: I. Enrollment, clinical, fluid protocols	43
Application of the ATN classification scheme in a population without dementia: Findings from the EPAD cohort	43
MRI‐assessed locus coeruleus integrity is heritable and associated with multiple cognitive domains, mild cognitive impairment, and daytime dysfunction	43
Validity of the 2014 traumatic encephalopathy syndrome criteria for CTE pathology	42
Concomitant neurodegenerative pathologies contribute to the transition from mild cognitive impairment to dementia	42
A novel tau‐based rhesus monkey model of Alzheimer's pathogenesis	41
Diversity in Alzheimer's disease drug trials: The importance of eligibility criteria	41
First amyloid β1‐42 certified reference material for re‐calibrating commercial immunoassays	41
MarkVCID cerebral small vessel consortium: II. Neuroimaging protocols	41
Potential role of chitinase‐3‐like protein 1 (CHI3L1/YKL‐40) in neurodegeneration and Alzheimer's disease	40
The costs of developing treatments for Alzheimer's disease: A retrospective exploration	40
Characterizing plasma NfL in a community‐dwelling multi‐ethnic cohort: Results from the HABLE study	39
Plasma P‐tau181 to Aβ42 ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer's disease patients with concomitant cerebrovascular disease	39
Consideration of sex and gender in Alzheimer's disease and related disorders from a global perspective	39
Precision prevention of Alzheimer's and other dementias: Anticipating future needs in the control of risk factors and implementation of disease‐modifying therapies	39
Plasma IL‐12/IFN‐γ axis predicts cognitive trajectories in cognitively unimpaired older adults	38
The AHEAD 3‐45 Study: Design of a prevention trial for Alzheimer's disease	38
ABCA7 and the altered lipidostasis hypothesis of Alzheimer's disease	38
Mediterranean and Western diet effects on Alzheimer's disease biomarkers, cerebral perfusion, and cognition in mid‐life: A randomized trial	38
Daytime napping and Alzheimer's dementia: A potential bidirectional relationship	37
Bayes analysis supports null hypothesis of anti‐amyloid beta therapy in Alzheimer's disease	37
Brain functional network integrity sustains cognitive function despite atrophy in presymptomatic genetic frontotemporal dementia	37
APOE interacts with tau PET to influence memory independently of amyloid PET in older adults without dementia	36
Head injury and 25‐year risk of dementia	36
Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer's disease	36
Dementia in Africa: Current evidence, knowledge gaps, and future directions	36
The economic cost of delirium: A systematic review and quality assessment	36
Dietary fatty acids and risk of Alzheimer's disease and related dementias: Observations from the Washington Heights‐Hamilton Heights‐Inwood Columbia Aging Project (WHICAP)	35
Long‐term community noise exposure in relation to dementia, cognition, and cognitive decline in older adults	35
Small vessel disease more than Alzheimer's disease determines diffusion MRI alterations in memory clinic patients	35
Sex differences in the behavioral variant of frontotemporal dementia: A new window to executive and behavioral reserve	35
APOE and dementia – resequencing and genotyping in 105,597 individuals	35
Actigraphy‐estimated sleep and 24‐hour activity rhythms and the risk of dementia	34
Increased APOE ε4 expression is associated with the difference in Alzheimer's disease risk from diverse ancestral backgrounds	34
Alzheimer's disease alters oligodendrocytic glycolytic and ketolytic gene expression	34
The Longitudinal Early‐onset Alzheimer's Disease Study (LEADS): Framework and methodology	34
Distinct effects of beta‐amyloid and tau on cortical thickness in cognitively healthy older adults	34
Impact of COVID‐19 on the Onset and Progression of Alzheimer's Disease and Related Dementias: A Roadmap for Future Research	33
Tau and apolipoprotein E modulate cerebrovascular tight junction integrity independent of cerebral amyloid angiopathy in Alzheimer's disease	33
Reproductive period and dementia: A 44‐year longitudinal population study of Swedish women	33
Proton pump inhibitors act with unprecedented potencies as inhibitors of the acetylcholine biosynthesizing enzyme—A plausible missing link for their association with incidence of dementia	33
Sequences of cognitive decline in typical Alzheimer's disease and posterior cortical atrophy estimated using a novel event‐based model of disease progression	32
Medical comorbidities and ethnicity impact plasma Alzheimer's disease biomarkers: Important considerations for clinical trials and practice	32
Mitophagy alterations in Alzheimer's disease are associated with granulovacuolar degeneration and early tau pathology	32
A critical appraisal of tau‐targeting therapies for primary and secondary tauopathies	32
Speech‐in‐noise hearing impairment is associated with an increased risk of incident dementia in 82,039 UK Biobank participants	31
Suicide risk in first year after dementia diagnosis in older adults	31
Alzheimer's disease biomarkers in Black and non‐Hispanic White cohorts: A contextualized review of the evidence	31
Association of plasma biomarkers, p‐tau181, glial fibrillary acidic protein, and neurofilament light, with intermediate and long‐term clinical Alzheimer's disease risk: Results from a prospective coho	31
Water exchange rate across the blood‐brain barrier is associated with CSF amyloid‐β 42 in healthy older adults	31
Apathy in presymptomatic genetic frontotemporal dementia predicts cognitive decline and is driven by structural brain changes	30
The APOE ε4 exerts differential effects on familial and other subtypes of Alzheimer's disease	30
Reactive or transgenic increase in microglial TYROBP reveals a TREM2‐independent TYROBP–APOE link in wild‐type and Alzheimer's‐related mice	30
State‐of‐the‐art of lumbar puncture and its place in the journey of patients with Alzheimer's disease	30
Salivary lactoferrin as biomarker for Alzheimer's disease: Brain‐immunity interactions	29
Association of diabetes with stroke and post‐stroke dementia: A population‐based cohort study	29
Increasing participant diversity in AD research: Plans for digital screening, blood testing, and a community‐engaged approach in the Alzheimer's Disease Neuroimaging Initiative 4	29
Genome‐wide association study of rate of cognitive decline in Alzheimer's disease patients identifies novel genes and pathways	29
APOE alleles’ association with cognitive function differs across Hispanic/Latino groups and genetic ancestry in the study of Latinos‐investigation of neurocognitive aging (HCHS/SOL)	29
Mild cognitive impairment among rural‐dwelling older adults in China: A community‐based study	28
Prevalence of dementia in India: National and state estimates from a nationwide study	28
Refined carbohydrate‐rich diet is associated with long‐term risk of dementia and Alzheimer's disease in apolipoprotein E ε4 allele carriers	28
Sex differences in dementia and response to a lifestyle intervention: Evidence from Nordic population‐based studies and a prevention trial	28
Mild behavioral impairment is associated with progression to Alzheimer's disease: A clinicopathological study	28
Functional insights from biophysical study of TREM2 interactions with apoE and Aβ1‐42	27
Early prevention of cognitive impairment in the community population: The Beijing Aging Brain Rejuvenation Initiative	27
Aducanumab: Appropriate use recommendations	27
Effect of periodontal treatment on preclinical Alzheimer's disease—Results of a trial emulation approach	27
The biogenesis and biology of amyloid β oligomers in the brain	27
Effects of cocoa extract and a multivitamin on cognitive function: A randomized clinical trial	27
Rural‐urban differences in diagnostic incidence and prevalence of Alzheimer's disease and related dementias	27
Brain health: Key to health, productivity, and well‐being	27
Decoding perineuronal net glycan sulfation patterns in the Alzheimer's disease brain	27

Mitochondrial ROS control neuronal excitability and cell fate in frontotemporal dementia	27
Expectations and clinical meaningfulness of randomized controlled trials	26
C‐reactive protein levels and risk of dementia—Observational and genetic studies of 111,242 individuals from the general population	26
Subjective cognitive decline and stage 2 of Alzheimer disease in patients from memory centers	26
Epidemiology of early onset dementia and its clinical presentations in the province of Modena, Italy	26
COVID‐19 breakthrough infections and hospitalizations among vaccinated patients with dementia in the United States between December 2020 and August 2021	26
The structural and social determinants of Alzheimer's disease related dementias	26
Unhealthy foods may attenuate the beneficial relation of a Mediterranean diet to cognitive decline	26
Differences between blood and cerebrospinal fluid glial fibrillary Acidic protein levels: The effect of sample stability	26
	26
Apolipoprotein B is a novel marker for early tau pathology in Alzheimer's disease	26
Brain structures and networks responsible for stimulation‐induced memory flashbacks during forniceal deep brain stimulation for Alzheimer's disease	25
Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer's disease and frontotemporal disorders in clinical settings	25
Genome‐wide transcriptome analysis identifies novel dysregulated genes implicated in Alzheimer's pathology	25
Comparative analytical performance of multiple plasma Aβ42 and Aβ40 assays and their ability to predict positron emission tomography amyloid positivity	25
Targeting increased levels of APP in Down syndrome: Posiphen‐mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model	25
Exploratory analysis of mtDNA haplogroups in two Alzheimer's longitudinal cohorts	25
ATN incorporating cerebrospinal fluid neurofilament light chain detects frontotemporal lobar degeneration	25
Shift work and incidence of dementia: A Danish Nurse Cohort study	25
Clinical performance and robustness evaluation of plasma amyloid‐β42/40 prescreening	25
Biofluid‐based biomarkers for Alzheimer's disease–related pathologies: An update and synthesis of the literature	25
Cancer and risk of Alzheimer's disease: Small association in a nationwide cohort study	25
Towards clinical application of tau PET tracers for diagnosing dementia due to Alzheimer's disease	25
Biphasic cortical macro‐ and microstructural changes in autosomal dominant Alzheimer's disease	24
Lifestyle, multi‐omics features, and preclinical dementia among Chinese: The Taizhou Imaging Study	24
Tau pathologies mediate the association of blood pressure with cognitive impairment in adults without dementia: The CABLE study	24
Blood polyunsaturated omega‐3 fatty acids, brain atrophy, cognitive decline, and dementia risk	24
Association of Life's Simple 7 with incident dementia and its modification by the apolipoprotein E genotype	24
The BIN1 rs744373 Alzheimer's disease risk SNP is associated with faster Aβ‐associated tau accumulation and cognitive decline	24
Hypothesis: JNK signaling is a therapeutic target of neurodegenerative diseases	24
Test‐retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction models	24
TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels	24
Integrative functional genomic analysis of intron retention in human and mouse brain with Alzheimer's disease	24
The effect of adherence on cognition in a multidomain lifestyle intervention (FINGER)	24
In situ spatial glycomic imaging of mouse and human Alzheimer's disease brains	24
Late‐life physical activity relates to brain tissue synaptic integrity markers in older adults	24
Amyloid‐beta misfolding and GFAP predict risk of clinical Alzheimer's disease diagnosis within 17 years	24
Early dementia diagnosis, MCI‐to‐dementia risk prediction, and the role of machine learning methods for feature extraction from integrated biomarkers, in particular for EEG signal analysis	24
Detection of Alzheimer's disease amyloid beta 1‐42, p‐tau, and t‐tau assays	24
Midlife lipid and glucose levels are associated with Alzheimer's disease	23
Slowing gait speed precedes cognitive decline by several years	23
Reduced synchrony in alpha oscillations during life predicts post mortem neurofibrillary tangle density in early‐onset and atypical Alzheimer's disease	23
Blood extracellular vesicles carrying synaptic function‐ and brain‐related proteins as potential biomarkers for Alzheimer's disease	23
Systematic in silico analysis of clinically tested drugs for reducing amyloid‐beta plaque accumulation in Alzheimer's disease	23
A prognostic model for overall survival in sporadic Creutzfeldt‐Jakob disease	23
Microglial INPP5D limits plaque formation and glial reactivity in the PSAPP mouse model of Alzheimer's disease	23
Neurodegeneration and astrogliosis in the entorhinal cortex in Alzheimer's disease: Stereological layer‐specific assessment and proteomic analysis	23
Perspective on the “African American participation in Alzheimer disease research: Effective strategies” workshop, 2018	23
Plasma proteins, cognitive decline, and 20‐year risk of dementia in the Whitehall II and Atherosclerosis Risk in Communities studies	23
Association of cardiovascular risk burden with risk of dementia and brain pathologies: A population‐based cohort study	23
CSF biomarkers and plasma p‐tau181 as predictors of longitudinal tau accumulation: Implications for clinical trial design	23
Cardiometabolic multimorbidity accelerates cognitive decline and dementia progression	23
Tau phosphorylation sites serine202 and serine396 are differently altered in chronic traumatic encephalopathy and Alzheimer's disease	23
Elevated plasma neurofilament light predicts a faster rate of cognitive decline over 5 years in participants with objectively‐defined subtle cognitive decline and MCI	22
How can population‐based studies best be utilized to reduce the global impact of dementia? Recommendations for researchers, funders, and policymakers	22
Open Peer Commentary to “Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE Trials as reported by Biogen December 2019”	22
Quantifying dementia prevention potential in the FINGER randomized controlled trial using the LIBRA prevention index	22
Harmonizing neuropsychological assessment for mild neurocognitive disorders in Europe	22
Equivalence of plasma p‐tau217 with cerebrospinal fluid in the diagnosis of Alzheimer's disease	22
Impact of increased APP gene dose in Down syndrome and the Dp16 mouse model	22
Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview	22
Increased β‐site APP cleaving enzyme 1‐mediated insulin receptor cleavage in type 2 diabetes mellitus with cognitive impairment	22
Comparison of CSF phosphorylated tau 181 and 217 for cognitive decline	22
Quantifying progression in primary progressive aphasia with structural neuroimaging	22
White matter hyperintensities and longitudinal cognitive decline in cognitively normal populations and across diagnostic categories: A meta‐analysis, systematic review, and recommendations for future	22
Characteristics of subjective cognitive decline associated with amyloid positivity	21
Identification of the Aβ37/42 peptide ratio in CSF as an improved Aβ biomarker for Alzheimer's disease	21
Self‐reported obstructive sleep apnea, amyloid and tau burden, and Alzheimer's disease time‐dependent progression	21
Non‐coding variants in MYH11, FZD3, and SORCS3 are associated with dementia in women	21
Plasma amyloid beta predicts conversion to dementia in subjects with mild cognitive impairment: The BALTAZAR study	21
APP accumulates with presynaptic proteins around amyloid plaques: A role for presynaptic mechanisms in Alzheimer's disease?	21
Global, regional, and national trends of dementia incidence and risk factors, 1990–2019: A Global Burden of Disease study	21
MAPT haplotype–stratified GWAS reveals differential association for AD risk variants	21
Anosmia, mild cognitive impairment, and biomarkers of brain aging in older adults	21
A combination model of AD biomarkers revealed by machine learning precisely predicts Alzheimer's dementia: China Aging and Neurodegenerative Initiative (CANDI) study	21
Expected wait times for access to a disease‐modifying Alzheimer's treatment in the United States	21
Difficulty and help with activities of daily living among older adults living alone with cognitive impairment	21
Association of life‐course depression with the risk of dementia in late life: A nationwide twin study	21
Addressing the disparities in dementia risk, early detection and care in Latino populations: Highlights from the second Latinos & Alzheimer's Symposium	20
APOE genotype, hippocampus, and cognitive markers of Alzheimer's disease in American Indians: Data from the Strong Heart Study	20
The temporal onset of the core features in dementia with Lewy bodies	20
Cerebral small vessel disease burden and cognitive and functional outcomes after stroke: A multicenter prospective cohort study	20
Genetic risk, adherence to a healthy lifestyle, and cognitive decline in African Americans and European Americans	20
Ophthalmic conditions associated with dementia risk: The Cardiovascular Health Study	20
Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia	20
Pathogenesis of sporadic Alzheimer's disease by deficiency of NMDA receptor subunit GluN3A	20
Automated detection of mild cognitive impairment and dementia from voice recordings: A natural language processing approach	20
Recommendations to address key recruitment challenges of Alzheimer's disease clinical trials	20
Can active life mitigate the impact of diabetes on dementia and brain aging?	20
Genome‐wide association and multi‐omics studies identify MGMT as a novel risk gene for Alzheimer's disease among women	20
Generalizability of findings from a clinical sample to a community‐based sample: A comparison of ADNI and ARIC	20
Why the cognitive “fountain of youth” may be upstream: Pathways to dementia risk and resilience through social connectedness	19
Lower serum testosterone concentrations are associated with a higher incidence of dementia in men: The UK Biobank prospective cohort study	19
Characterization of dementia with Lewy bodies (DLB) and mild cognitive impairment using the Lewy body dementia module (LBD‐MOD)	19
Longitudinal association of apolipoprotein E and sleep with incident dementia	19